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Abstract
Background: Recent studies revealed that glucokinase regulatory protein (GCKR) variants (rs780094 and rs1260326)
are associated with serum triglycerides and plasma glucose levels. Here we analyzed primarily the association of
these two variants with the lipid profile and plasma glucose levels in Hungarian subjects with type 2 diabetes
mellitus and metabolic syndrome; and also correlated the genotypes with the carotid intima-media thickness
records.
Methods: A total of 321 type 2 diabetic patients, 455 metabolic syndrome patients, and 172 healthy controls were
genotyped by PCR-RFLP.
Results: Both GCKR variants were found to associate with serum triglycerides and with fasting plasma glucose.
However, significant association with the development of type 2 diabetes mellitus and metabolic syndrome could
not be observed. Analyzing the records of the patients, a positive association of prevalence the GCKR homozygous
functional variants and carotid intima-media thickness was found in the metabolic syndrome patients.
Conclusions: Our results support that rs780094 and rs1260326 functional variants of the GCKR gene are inversely
associated with serum triglycerides and fasting plasma glucose levels, as it was already reported for diabetic and
metabolic syndrome patients in some other populations. Besides this positive replication, as a novel feature, our
preliminary findings also suggest a cardiovascular risk role of the GCKR minor allele carriage based on the carotid
intima-media thickness association.
1. Background
Type 2 diabetes mellitus (T2DM) is characterized by
elevated plasma glucose level as a result of impaired
beta-cell function and/or peripheral insulin resistance
[1]. Impaired glucose regulation is a major hallmark of
metabolic syndrome (MS), however it is a more complex
disorder featured by visceral obesity, elevated serum tri-
glycerides, low level of HDL-cholesterol and raised
blood pressure [2]. The prevalence of T2DM and MS is
very high in the industrialized countries contributing to
a considerably increased atherosclerotic burden and car-
diovascular risk. Both of them are multifactorial dis-
eases, besides several environmental factors, such as
cigarette smoking, obesity, lack of exercise, bad nutrition
habits and genetic factors are also contributed to the
pathogenesis.
G l u c o k i n a s e( G C K )i sap r e d o m i n a n tg l u c o s ep h o s -
phorylating enzyme expressed in the liver and in the
beta-cells of the Langerhans islets, playing a pivotal role
in the glucose-stimulated insulin release as a physiologi-
cal glucose-sensor [3]. Pancreatic islets and the liver
contain a regulatory protein (glucokinase regulatory
protein, GCKR), which inhibits GCK in an allosteric
manner with respect to glucose concentration by
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any medium, provided the original work is properly cited.forming an inactive heterodimer. The inhibitory effect of
GCKR is enhanced by fructose-6-phosphate and antago-
nized by fructose-1-phosphate [4]. The 27 kb GCKR
gene is located on chromosome 2p23 containing 19
exons and encodes a 68 kDa protein [5,6]. Genome-
wide association studies showed, that common func-
tional variants of the GCKR gene are associated with
fasting plasma glucose, insulin levels, and both serum
triglycerides and low/high-density lipoprotein choles-
terol levels, thus, single nucleotide polymorphisms
(SNPs) rs780094 and rs1260326 reduce fasting plasma
glucose concentration and insulin levels and improve
insulin resistance, while inversely increase fasting and
postprandial serum triglycerides [7-16]. More recently,
both functional variants of the GCKR gene were widely
investigated as candidate T2DM susceptibility variants,
and a protective nature against T2DM [8,10,17,18].
The primary goal of the current work was to study the
possible association of rs780094 and rs1260326 of the
GCKR gene on metabolic and cardiovascular risk traits
in Hungarian patients, which nation differs from the
surrounding European populations in its origin [19].
The pooled ultrasonography records of the patients
enabled us to study also the carotid intima-media thick-
ness association.
2. Methods
2.1. Study population
In a genetic association study we examined two com-
mon variants (rs780094 and rs1260326) of the GCKR
gene. The study population comprised 321 subjects
with T2DM (172 males, 149 females, mean age: 61.3 ±
12.2 years, range: 27-89 years), 455 subjects with MS
( 2 0 0m a l e s ,2 5 5f e m a l e s ,m e a na g e :6 1 . 7±1 0 . 7 ,r a n g e :
26-85 years) and 172 healthy control subjects (49 males,
123 females, mean age: 56.5 ± 15.2, range: 19-92 years).
All 948 study participants were selected from the Cauca-
sian Hungarian population.
All patients were enrolled from the 2
nd Department of
Medicine and Nephrological Center, University of Pécs,
Hungary and from the Aladár Petz Hospital, Győr,
Hungary. T2DM was diagnosed according to the criteria
of the World Health Organization [1]. Waist circumfer-
ence data were not available, therefore MS was diag-
nosed according to modified criteria of the Adult
Treatment Panel III of National Cholesterol Education
Program [20], defined as presence of at least 3 of the
following factors at the time of diagnosis: body mass
index (BMI) > 30 kg/m
2, serum triglycerides≥1.70
mmol/l and/or lipid lowering treatment; serum HDL-
cholesterol <0.9/1.1 mmol/l (male/female); systolic blood
pressure ≥130 mmHg and diastolic blood pressure≥85
mmHg and/or antihypertensive treatment; fasting
plasma glucose ≥5.60 mmol/l and/or antiglycemic
treatment. Hypertriglyceridemia was defined as fasting
serum triglycerides≥1.7 mmol/l. Controls were gathered
from trauma units, blood donors, medical staff and uni-
versity students, they were free from any single clinical
or laboratory sign of T2DM or MS; their medical history
were also free from any systemic or organ-specific dis-
ease. Exclusion criteria were as follows: pregnancy, fever,
sepsis, malignancies, autoimmune systemic diseases,
alcohol or drog abuse, severe heart failure, hepatic
failure.
DNA samples and the clinical data were deposited into
the Central Biobank governed by the University of Pécs, as
part of the National Biobank Network of Hungary http://
www.biobank.hu, approved by the national Scientific
Research Ethics Committee (ETT TUKEB). The Biobank
belongs to the pan-European Biobanking and Biomolecu-
lar Resources Research Infrastructure (BBMRI) prepara-
tory phase project http://bbmri.eu/bbmri/. All participants
gave their informed consent and the study followed the
principles of the Helsinki Declaration.
2.2. Biochemical and clinical data
All participants underwent a detailed medical examina-
tion, including anamnestic history, physical examination,
and estimation of cardiovascular risk factors, laboratory
and urine analysis, electrocardiography. Laboratory para-
meters were assessed using routine methods from fast-
ing blood samples. BMI was calculated as weight (kg)
divided by height (m
2). Carotid intima-media thickness
(CIMT) was measured by B-mode ultrasound device
with a high resolution 10 MHz linear transducer
(ALOKA 4000, Tokyo, Japan) in a plaque free region of
both carotid arteries at 2 cm proximal to the carotid
bulb on the common carotid artery and at the origin of
the internal carotid artery. The ultrasound transducer
was placed in an angle of 90° of the vessel wall. CIMT
values were obtained from the above mentioned sites
and were defined as means of the maximal CIMT mea-
surements for the right and left sides. Each participants
were scanned in a standardized environment, in the
same room, by the same examiner, using the same
instrument.
2.3. Genotyping
DNA was isolated from peripheral blood leukocytes by
standard salting out method. For polymerase chain reac-
tion amplification, the following primers (MWG-Biotech
AG, Ebersberg, Germany) were used: GCKR rs1260326:
forward 5’-TGC AGA CTA TAG TGG AGC CG-3’ and
reverse 5’- C A TC A CA T GG C CA C TG C TT T - 3 ’;
GCKR rs780094: forward 5’-GAT TGT CTC AGG CAA
ACC TGG TAG-3’ and reverse 5’-CTA GGA GTG
GTG GCA TAC ACC TG-3’. An MJ Research PTC-200
thermal cycler (Bio-Rad, Hercules, CA, USA) was used
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ing: predenaturation at 96°C for 2 min; followed by
35 cycles of denaturation at 96°C for 20 sec (rs1260326),
30 cycles of denaturation at 96°C for 20 sec (rs780094);
annealing at 60°C for 20 sec (rs1260326), and at 62°C
for 30 sec (rs780094); primer extension for 30 sec at
72°C; and final extension at 72°C for 5 min. The ampli-
cons were digested by HpaII restriction endonuclease
(rs1260326) and PscI (rs780094) (Fermentas, Burlington,
ON, Canada). The digestion of 231 bp amplicon of
rs1260326 CC genotype resulted in 18, 63, 150 bp frag-
ments; the TT genotype 18 and 213 bp; while the het-
erozygous genotype 18, 63, 150, 213 bp fragments. For
the rs780094 427 bp amplicon the following fragments
were detected: GG genotype 62, 177, 188 bp; AA geno-
type 62, 365 bp; heterozygous genotype 62, 177, 188,
365 bp fragments. All methods were designed to include
an obligate cleavage site on the amplicon to enable us
to control the efficacy of the digestion.
2.4. Statistical analysis
BMI, fasting plasma glucose concentrations, serum trigly-
cerides and HDL-cholesterol levels were log-transformed
because of non-normal distribution. Results were
expressed as mean ± SD and median (minimum-
maximum) as appropriate according to distribution. Kol-
mogorov-Smirnov test was used to assess sample distri-
bution. Chi-square test was carried out to determine
whether genotype distributions followed the Hardy-
Weinberg equilibrium and to compare other qualitative
data. Clinical and biochemical characteristics of the study
participants at baseline were compared with one-way
ANOVA. Statistical differences between the individual
GCKR genotypes were assessed by analysis of covariance
(ANCOVA) adjusted for gender, age, BMI. Trend was
examined with Jonckheere-Terpstra test. Logistic regres-
sion analysis models were used to evaluate individual
effects of genotypes as possible risk factors; multivariate
regression analysis models were adjusted for age, gender,
total serum cholesterol, coronary artery diseases (CAD)
and statin therapy. All statistical procedures were per-
formed using the SPSS 15.0 software (SPSS Inc., Chicago,
IL, USA). P values ≤ 0.05 were considered statistically
significant.
3. Results
Major clinical and biochemical features of the patients
and controls are summarized in Table 1; the genotype
profiles including the minor allele frequencies are
shown in Table 2. All genotypes were in Hardy-
Weinberg equilibrium. Allele frequencies were similar in
the study groups.
Table 3 shows the lipid parameters examined, the
plasma glucose concentrations, BMI, and CIMT data for
each analyzed SNP of the GCKR gene. BMI is not asso-
ciated either with rs780094 or with rs1260326, however
plasma glucose levels were associated with both variants
significantly (p < 0.05). We observed association of the
minor allele of rs780094 and rs1260326 with elevated
serum triglycerides in all groups. We found no relation-
ship between variants of GCKR gene and total serum
cholesterol levels, however HDL-cholesterol level was
significantly lower in subjects homozygous for the
minor allele for both rs780094 and rs1260326, but only
in T2DM patients, moreover LDL-cholesterol was signif-
icantly elevated in homozygous patients, but only in the
MS group. We also correlated the CIMT of the patients
with T2DM and MS. The homozygous minor alleles
were associated with increased carotid intima-media
thickness in metabolic syndrome patients.
Table 4. shows the relative risk of hypertriglyceridemia
for variants rs780094 and rs1260326 at GCKR gene cal-
culated by the multiple logistic regression analysis mod-
els. Regression analysis revealed that both rs780094 and
rs1260326 confer a significant susceptibility for the
development of hypertriglyceridemia; after adjusting the
results for age, gender, total serum cholesterol, CAD
and statin therapy.
4. Discussion
Genome wide association studies revealed an association
between SNP rs780094 of GCKR gene and hypertrigly-
ceridemia in subjects with T2DM [12]. This association
was replicated in other large diabetic and non-diabetic
population samples [10,13]. Besides the triglyceride
levels, the SNP was also associated with lower plasma
glucose levels, and with lower risk for the development
of T2DM [12,17]. Another SNP of GCKR (rs1260326,
P446L) is in strong linkage disequilibrium (r
2 = 0.96)
with rs780094 according the HapMap II data http://
www.hapmap.org. In Danish diabetic twins and in the
Dutch population rs1260326 was found to be associated
with increased insulin secretion and lower plasma glu-
cose [7,21], and association with elevated triglycerides
was also confirmed in different populations [8,9]. By
contrast, the rs1260326 allele was found to correlate
with metabolic traits, but not with susceptibility for the
development of metabolic syndrome in the Scandinavian
population [22].
In the current study, we could replicate the previously
reported positive associations of the two functional
variants of GCKR gene (rs780094 and rs1260326) and
triglyceride/glucose metabolism in the Hungarian popu-
lation; our results confirmed the inverse association with
serum triglycerides and plasma glucose levels in T2DM,
MS and healthy control subjects.
GCKR competitively inhibits GCK, playing a major
role in the regulation of insulin secretion and glycogen
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gene for T2DM. In the presence of low glucose concen-
trations both GCK and GCKR are localized in the
nucleus of hepatocytes due to metabolic alterations
(higher glucose or fructose concentrations) GCK, but
not GCKR, translocates into the cytoplasm [23,24].
Furthermore, GCKR is also play a role in the nuclear-
cytoplasmic transport and in the protection against
degradation of GCK [25-27]. Animal models have also
shown that GCKR also regulates the posttranscriptional
expression of GCK. Taken all these data together, it is
obvious that functional change in this regulatory protein
may considerably influence the glucose metabolism.
In SNP rs1260326 of the GCKR a C/T change results
in a proline to leucine substitution in the amino
sequence of the encoded protein. This change is very
likely to modify the structure of the protein and if this
structural alteration is in the binding site of fructose-6-
phosphate or fructose-1-phosphate it can influence the
function of the protein.
Increased glycolitic flux, downregulated glucose-6-
phosphatase and upregulated GCK, phosphofructokinase
and fatty acid synthase result in an increased glycogen
synthesis and malonil-CoA concentration and an
increased VLDL triglyceride production. These meta-
bolic changes might potentially explain the lower plasma
glucose and higher triglyceride levels, however the exact
mechanism remains to be elucidated [8,28].
Measuring CIMT, as a surrogate marker of cardiovascu-
lar disease, is widely used and validated method in both
patients with or without T2DM to detect subclinical ather-
osclerosis, however to predict the relative risk for the devel-
opment of future cardiovascular diseases is much more
difficult and presumes holistic interpretation of the com-
plex interactions between both genetic and clinical factors.
Besides the conventional cardiovascular risk factors
as hypertension, high LDL-cholesterol level, low
HDL-cholesterol level, hypertriglyceridemia, also
the level of advanced glycation endproducts (e.g. N-
epsilon-carboxymethyllysine) confer an independent
significant risk for cardiovascular diseases and asso-
ciated with atherosclerotic lesions not only in diabetic
but in normoglycemic subjects [29-34].
Common variants in the GCKR gene were referred to
be associated also with higher C-reactive protein levels,
which is a favorable atherosclerotic marker. Here we
also investigated the lipid traits and the CIMT, which
was proved an independent preclinical marker of athero-
sclerosis and CAD.
5. Conclusions
Our results support that rs780094 and rs1260326 func-
tional variants of the GCKR gene are inversely
Table 1 Clinical and biochemical features of the patients with T2DM, MS and control subjects.
Controls
n = 172
T2DM
n = 321
MS
n = 455
p-value
Gender (male/female) 49/123 172/149 200/255 <0.001
Age (years) 56.5 ± 15.2 61.3 ± 12.2 61.7 ± 10.7 <0.001*
Body mass index (kg/m
2) 23.9 ± 2.15 29.5 ± 5.87 33.3 ± 5.48 <0.001*
#
Fasting plasma glucose (mmol/l) N/A 8.70 (2.30-22.8) 9.00 (3.00-30.8) 0.249
Serum total cholesterol (mmol/l) 4.78 ± 1.10 5.16 ± 1.25 5.37 ± 0.94 <0.001
†
Serum LDL-cholesterol (mmol/l) N/A 2.74 ± 0.86 2.83 ± 0.84 0.256
Serum HDL-cholesterol (mmol/l) N/A 1.19 (0.55-2.12) 1.23 (0.55-2.49) <0.001
Serum triglycerides (mmol/l) 1.50 (0.50-3.60) 1.62 (0.35-14.8) 1.98 (0.35-14.48) <0.001
#†
CIMT (mm) N/A 0.88 ± 0.44 1.22 ± 0.74 0.265
Systolic blood pressure (mmHg) N/A 130 (87.0-210) 140 (70.0-200) <0.001
Diastolic blood pressure (mmHg) N/A 80.0 (50.0-130) 80.0 (60.0-137) <0.001
Hypertension (%) 22.7 77.5 90.4 <0.001*
Coronary heart disease (%) 4.1 25.3 25.4 <0.001*
CIMT, carotid intima-media thickness; HDL, high density lipoprotein; LDL, low density lipoprotein; N/A: data not available; MS: metabolic syndrome, T2DM: type 2
diabetes mellitus; * Controls vs. T2DM and MS; # T2DM vs. MS; † Controls vs. MS; Data are means ± SD or median (minimum-maximum) as appropriate.
Table 2 Genotype distribution (case number) and allele
frequencies (%) in control subjects and in patients with
T2DM and MS.
Controls T2DM MS
GCKR
(rs780094)
GG 44 77 121
GA 93 151 217
AA 35 78 100
A allele (%) 47.4 46.9 47.6
GCKR
(rs1260326)
CC 48 80 118
CT 80 155 219
TT 44 63 91
T allele (%) 48.8 47.1 46.8
T2DM: subjects with type 2 diabetes mellitus; MS: subjects with metabolic
syndrome
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glucose levels. As a novel feature, in this report we
found, that homozygous rs780094 and rs1260326 GCKR
gene variants are associated with CIMT.
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Table 3 Body mass index, fasting plasma glucose, lipid profile and carotid intima-media thickness in subjects with
metabolic syndrome, type 2 diabetes mellitus and controls by individual genotypes (A: GCKR rs780094; B: GCKR
rs1260326)
Controls T2DM MS
GG
n=4 4
GA
n=9 3
AA
n=3 5
GG
n=7 7
GA
n = 151
AA
n=7 8
GG
n = 121
GA
n = 217
AA
n = 100
BMI (kg/m
2) 23.6
(21.2-28.6)
23.9
(15.8-32.8)
23.8
(13.7-26.8)
29.2
(17.0-48.6)
29.0
(18.3-45.9)
27.3
(18.3-43.4)
32.5
(22.5-52.5)
32.7
(20.4-48.1)
32.9
(19.4-60.5)
FPG (mmol/l) N/A N/A N/A 9.50
(3.00-17.0)
9.20
(3.80-22.8)
8.90
(2.30-17.1)*
9.60
(3.80-19.1)
8.80
(3.00-30.8)
8.50
(4.51-16.6)*
Serum triglycerides
(mmol/l)
1.35
(0.50-2.90)
1.50
(0.80-3.60)
1.70
(0.70-3.20)*
1.77
(0.38-8.23)
1.81
(0.35-6.22)
2.24
(0.66-14.8)*
2.07
(0.49-7.76)
2.68
(0.35-14.2)*
3.07
(0.78-12.3)#
A Serum total-cholesterol
(mmol/l)
5.48 ± 0.80 5.44 ± 0.94 5.04 ± 1.04 5.01 ± 1.02 4.60 ± 1.12 4.75 ± 1.10 5.03 ± 1.05 5.15 ± 1.36 5.35 ± 1.26
Serum HDL-cholesterol
(mmol/l)
N/A N/A N/A 1.39
(0.76-2.48)
1.25
(0.68-2.37)
1.19
(0.62-2.49)*
1.21
(0.77-1.99)
1.22
(0.55-2.12)
1.17
(0.79-1.88)
Serum LDL-cholesterol
(mmol/l)
N/A N/A N/A 2.84 ± 0.90 2.64 ± 0.83 2.75 ± 0.89 2.08 ± 0.81 2.70 ± 0.83 3.06 ± 0.92*
CIMT (mm) N/A N/A N/A 0.81 ± 0.42 0.86 ± 0.38 0.95 ± 0.44 0.79 ± 0.28 0.87 ± 0.32 1.06 ± 0.26*
Controls T2DM MS
CC
n=4 8
TC
n=8 0
TT
n=4 4
CC
n=8 0
TC
n = 155
TT
n=6 3
CC
n = 118
TC
n = 219
TT
n=9 1
BMI (kg/m
2) 23.7
(20.8-28-6)
23.8
(15.8-32.8)
23.8
(13.7-26.8)
29.2
(17.0-37.6)
29.3
(18.3-45.9)
28.9
(18.3-38.6)
31.8
(20.4-49.57)
32.8
(19.4-52.5)
33.4
(25.0-60.5)
FPG (mmol/l) N/A N/A N/A 9.05
(3.00-16.9)
8.90
(2.30-17.1)
8.70
(2.30-22.8)*
9.80
(3.20-20.0)
8.60
(3.90-30.8)
8.40
(3.00-16.6)*
Serum triglycerides
(mmol/l)
1.51
(0.50-2.90)
1.55
(0.70-2.90)
1.68
(0.80-3.60)*
1.45
(0.35-4.28)
1.87
(0.39-8.23)*
2.32
(0.59-14.9)*
2.19
(0.70-7.86)
2.72
(0.35-14.4)*
2.91
(0.78-11.5)*
B Serum total-cholesterol
(mmol/l)
5.44 ± 0.87 5.41 ± 0.96 5.20 ± 0.99 5.03 ± 1.11 4.64 ± 0.97 4.72 ± 1.32 5.10 ± 1.02 5.21 ± 1.38 5.20 ± 1.27
Serum HDL-cholesterol
(mmol/l)
N/A N/A N/A 1.39
(0.76-2.48)
1.27
(0.68-2.47)
1.17
(0.62-2.49)*
1.23
(0.70-1.96)
1.16
(0.55-2.12)
1.23
(0.79-1.88)
Serum LDL-cholesterol
(mmol/l)
N/A N/A N/A 2.85 ± 0.88 2.63 ± 0.78 2.78 ± 1.05 2.71 ± 0.81 2.85 ± 0.82 3.00 ± 0.93*
CIMT (mm) N/A N/A N/A 0.81 ± 0.39 0.88 ± 0.37 0.95 ± 0.42 0.83 ± 0.32 0.87 ± 0.35 1.05 ± 0.36*
* p < 0.05 vs. GG; # p < 0.001 vs. GG; BMI, body mass index; CIMT, carotid intima-media thickness; FPG, fasting plasma glucose; HDL, high-density lipoprotein;
LDL, low-density lipoprotein; MS, metabolic syndrome; T2DM, type 2 diabetes mellitus; Data are mean ± SD or median (minimum-maximum) as appropriate.
Table 4 Odds ratios at 95% confidence intervals (CI)
calculated by the multiple logistic regression analysis
models
Hypertriglyceridemia
Unadjusted model
Odds ratio
(95% CI)
Adjusted model
Odds ratio*
(95% CI)
GCKR (rs780094)
AA genotype
1.748
(1.256-2.435)
p = 0.001
5.335
(1.779-15.99)
p = 0.003
GCKR (rs1260326)
TT genotype
1.311
(1.078-1.596)
p = 0.007
4.523
(1.458-14.03)
p = 0.009
*Adjusted for: age, gender, BMI, serum total cholesterol, CAD, statins
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